Truqap is a kinase inhibitor that works by blocking pathways that assist the cancer cells endure and develop, so decreases cancer development. Truqap is from a class of medicines referred to as an AKT inhibitor. Truqap acquired FDA approval on November 17, 2023, immediately after positive outcomes in the CAPItello-291 https://billj665xit8.atualblog.com/profile